Parkinson’s disease-associated ATP13A2/PARK9 functions as a lysosomal H+,K+-ATPase

Mutations in the human ATP13A2 (PARK9), a lysosomal ATPase, cause Kufor-Rakeb Syndrome, an early-onset form of Parkinson’s disease (PD). Here, we demonstrate that ATP13A2 functions as a lysosomal H+,K+-ATPase. The K+-dependent ATPase activity and the lysosomal K+-transport activity of ATP13A2 are inhibited by an inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase, thapsigargin, and K+-competitive inhibitors of gastric H+,K+-ATPase, such as vonoprazan and SCH28080. Interestingly, these H+,K+-ATPase inhibitors cause lysosomal alkalinization and α-synuclein accumulation, which are pathological hallmarks of PD. Furthermore, PD-associated mutants of ATP13A2 show abnormal expression and function. Our results suggest that the H+/K+-transporting function of ATP13A2 contributes to acidification and α-synuclein degradation in lysosomes.

For all statistical analyses, confirm that the following items are present in in the figure legend, table legend, main text, or or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as as a discrete number and unit of of measurement A statement on on whether measurements were taken from distinct samples or or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of of all covariates tested A description of of any assumptions or or corrections, such as as tests of of normality and adjustment for multiple comparisons A full description of of the statistical parameters including central tendency (e.g. means) or or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or or associated estimates of of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on on the choice of of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of of the appropriate level for tests and full reporting of of outcomes Estimates of of effect sizes (e.g. Cohen's d, Pearson's r), ), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or or software that are central to to the research but not yet described in in published literature, software must be be made available to to editors and reviewers. We We strongly encourage code deposition in in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information. Takuto Fujii, Hideki Sakai Mar 21, 2023 The cDNA sequences were obtained by by an an ABI PRISM 3500 sequencer (Applied Biosystems). Western blotting was performed with LAS-4000 system (FujiFilm). Immunofluorescence images were visualized by by using a Zeiss LSM 780 laser scanning confocal microscope (Zeiss). Size extrusion chromatography was performed with AKTAexplorer 10 10 XT XT FPLC system (GE Healthcare). The radioactivity was visualized with Typhoon FLA 9500 (Cytiva).
The bands detected by by Western blotting were quantified with ImageJ software e (version: 1.8.0). The intensity of of immunofluorescence images was quantified with Zen 3.3 software (Zeiss).

March 2021
Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our policy

Human research participants
Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender
Population characteristics

Recruitment
Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative. No statistical methods were used to predetermine the sample size. All experimental data were obtained from three or more independent experiments to ensure each data point was reproducible.
No data was excluded in this study All experiments were done at least three times. The meaning of "n" in each figure is described in the figure legend in manuscript. All attempts for replication shows similar results.
Within each experimental regime, cell populations were assigned randomly to a siRNA, drug or control treatment.
The experimentators were blinded towards the code if necessary.